期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

硼替佐米治疗淋巴瘤新进展 被引量：5

原文传递
导出
摘要 硼替佐米作为第一个应用于临床的蛋白酶体抑制剂，通过影响多种细胞周期调控蛋白及NF—κB活性，发挥抗肿瘤作用。硼替佐米在多发性骨髓瘤（MM）的治疗中取得了令人鼓舞的疗效，是近年来MM药物治疗最重要的进展之一。淋巴瘤细胞中普遍存在NF—κB的组成性高表达，因此，硼替佐米可望成为治疗淋巴瘤一种新的选择。近年来国际间开展的一系列设计严格的临床试验表明硼替佐米治疗复发和难治套细胞淋巴瘤（MCL）、
作者 易树华 王亚非 邱录贵
机构地区 中国医学科学院、北京协和医学院血液学研究所、血液病医院
出处 《中华血液学杂志》 CAS CSCD 北大核心 2009年第4期285-288,共4页 Chinese Journal of Hematology
基金 卫生部临床学科重点项目（2007-2009）
关键词 淋巴瘤细胞 硼替佐米 药物治疗 蛋白酶体抑制剂 细胞周期调控 多发性骨髓瘤 套细胞淋巴瘤 临床试验
分类号 R686 [医药卫生—骨科学]
  • 相关文献

参考文献36

  • 1Pham LV,Tamayo AT, Yoshimura LC, et al. Inhibition of constitutive NF-kappaB activation in mantle cell lymphoma B cells leads to induction of cell cycle arrest and apoptosis. J Immunol, 2003, 171:88-95.
  • 2Fisher RI, Bernstein SH, Kahl BS, et al. Muhicenter phase Ⅱ study of bortezomib in patients with relapsed or refractory mantle cell lymphoma. J Clin Oneol, 2006, 24:4867-4874.
  • 3Goy A, Younes A, McLaughlin P, et al. Phase Ⅱ study of protea-some inhibitor bortezomib in relapsed or refractory B-cell non- Hodgkin' s lymphoma. J Clin Oncol, 2005, 23:667-675.
  • 4O' Connor OA, Wright J, Moskowitz C, et al. Phase Ⅱ clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin' s lymphoma and mantle cell lymphoma. J Clin Oncal, 2005, 23:6074584.
  • 5Strauss SJ, Maharaj L, Hoare H, et al. Bortezomib therapy in patients with relapsed or refractory lymphoma: potential correlation of In vitro sensitivity and tumor necrosis factor alpha response with clinical activity. J Clin Oncol, 2006, 24:2105-2112.
  • 6Belch A, Kouroukis CT, Crump M, et al. A phase Ⅱ study of bortezomib in mantle cell lymphoma: the National Cancer Institute of Canada Clinical Trials Group trial IND. 150. Ann Oncol, 2007, 18:116-121.
  • 7Goy A, Bernstein SH, Kahl BS,et al. Durable responses with bort-ezomib in patients with relapsed or refractory mantle cell lymphoma : updated time-to-event analyses of the multicenter phase 2 PIN- NACLE study. Ann Oncol, 2009, 20:520-525.
  • 8Kane RC, Dagher R, Farrell A, et al. Bortezomib for the treatment of mantle cell lymphoma. Clin Cancer Res, 2007, 13:5291- 5294.
  • 9Weigert O, Pastore A, Rieken M,et al. Sequence-dependent synergy of the proteasome inhibitor bortezomib and cytarabine in mantle cell lymphoma. Leukemia, 2007, 21:524-528.
  • 10Wang M, Hart XH, Zhang L,et al. Bortezomih is synergistic with rituximab and cyclophosphamide in inducing apoptosis of mantle cell lymphoma cells in vitro and in vivo. Leukemia, 2008, 22 : 179-185.

同被引文献84

  • 1计成阜,孙爱宁,金正明.输注美罗华引发严重不良反应1例[J].实用医学杂志,2006,22(16):1875-1875. 被引量：9
  • 2石远凯,于燕霞.非霍奇金淋巴瘤治疗进展[J].临床肿瘤学杂志,2006,11(7):481-485. 被引量：11
  • 3Wang M,Oki Y,Pro B,et al.Phase Ⅱ study of yttrium-90-ibritumomab tiuxetan in patients with relapsed or refractory mantle cell lymphoma.J Clin Oncol,2009,27:5213-5218.
  • 4Ghielmini M,Zucca E.How I treat mantle cell lymphoma.Blood,2009,114:1469-1476.
  • 5Obrador-Hevia A,Fernandez de Mattos S,Villalonga P,et al.Molecular biology of mantle cell lymphoma:from profiling studies to new therapeutic strategies.Blood Rev,2009,23:205-216.
  • 6Herrmann A,Hoster E,Zwingers T,et al.Improvement of overall survival in advanced stage mantle cell lymphoma.J Clin Oncol,2009,27:511-518.
  • 7Lenz G,Dreyling M,Hoster E,et al.Immunochemotherapy with rituximab and cyclophosphamide,doxorubicin,vincristine,and prednisone significantly improves response and time to treatment failure,but not long-term outcome in patients with previously untreated mantle cell lymphoma:results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG).J Clin Oncol,2005,23:1984-1992.
  • 8Evens AM,Winter JN,Hou N,et al.A phase Ⅱ clinical trial of intensive chemotherapy followed by consolidative stem cell transplant:long-term follow-up in newly diagnosed mantle cell lymphoma.Br J Hacmatol,2008,140:385-393.
  • 9Romaguera JE,Fayad L,Rodriguez MA,et al.High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-cvad alternating with rituximab plus high-dose methotrexate and cytarabine.J Clin Oncol,2005,23:7013-7023.
  • 10Epner EM,Unger J,Miller T,et al.A multi center trial of hyperCVAD + rituxan in patients with newly diagnosed mantle cell lymphoma.Blood,2007,110:387.

引证文献5

二级引证文献13

中华血液学杂志
2009年 第4期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部